Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young Adults

Part of paid clinical trials in Los Angeles, California.

Sponsor
Westat
Study ID
NCT06444360
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - 24 Years
Healthy Volunteers
Accepted

Interventions

  • IMPACT — BEHAVIORAL
    The IMPACT intervention includes 10 sessions: 2 sessions of HIV sexual risk reduction (RR) counseling, 1 session focused on orienting and rationale of behavioral activation (BA), 6 sessions integrating BA and sexual RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.
  • eSOC — BEHAVIORAL
    The eSOC group includes 2 sessions of HIV sexual RR counseling.

Study Details

The use of behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk.

Key Dates

Start date
Nov 4, 2025
Status verified
Jan 2026
Primary completion
Jul 31, 2028
Completion
Jul 31, 2028

Study Design

Enrollment
360 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: IMPACT Group
    Participants who report stimulant use in the context of condomless sex will be randomized using a 2:1 allocation ratio with two-thirds being allocated to the IMPACT intervention.
  • Active Comparator: Enhanced Standard of Care (eSOC) Group
    Participants who report stimulant use in the context of condomless sex will be randomized using a 2:1 allocation ratio with one-third being allocated to the eSOC intervention.

Primary Outcome Measure

Distinct acts of condomless sex without the protection of PrEP or viral suppression. [ Time Frame: Participants will recall and report acts of condomless sex and medication adherence for the 30 days prior to each of 4 visits: Baseline, Month 4, Month 8 and Month 12. ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
University of California, Los AngelesLos AngelesCalifornia90095
IMPACT 170 Staff
[email protected]
310-825-3094
Matthew Mimiaga, ScD, MPH (PRINCIPAL_INVESTIGATOR)
Brown UniversityProvidenceRhode Island02912
IMPACT 170 Staff
[email protected]
401-863-3292
Katie Biello, PhD, MPH (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By condition
HIV
By specialty
Infectious disease
By research site
University of California, Los Angeles· Los Angeles, CABrown University· Providence, RI

Related Studies